CR20230046A - Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma. - Google Patents

Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma.

Info

Publication number
CR20230046A
CR20230046A CR20230046A CR20230046A CR20230046A CR 20230046 A CR20230046 A CR 20230046A CR 20230046 A CR20230046 A CR 20230046A CR 20230046 A CR20230046 A CR 20230046A CR 20230046 A CR20230046 A CR 20230046A
Authority
CR
Costa Rica
Prior art keywords
bcl
inhibitor
combination
pharmaceutical compositions
hypomethylating agent
Prior art date
Application number
CR20230046A
Other languages
English (en)
Spanish (es)
Inventor
Emmelyne Dessein
Michael Robert Cooper
Lisa Mahnke
Original Assignee
Novartis Ag
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Servier Lab filed Critical Novartis Ag
Publication of CR20230046A publication Critical patent/CR20230046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20230046A 2020-07-31 2021-07-30 Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma. CR20230046A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CR20230046A true CR20230046A (es) 2023-04-11

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230046A CR20230046A (es) 2020-07-31 2021-07-30 Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma.

Country Status (15)

Country Link
US (1) US20230270748A1 (https=)
EP (1) EP4188387A1 (https=)
JP (1) JP2023537290A (https=)
KR (1) KR20230044452A (https=)
CN (1) CN116390735A (https=)
AU (1) AU2021316674A1 (https=)
BR (1) BR112023001307A2 (https=)
CA (1) CA3190276A1 (https=)
CL (1) CL2023000242A1 (https=)
CR (1) CR20230046A (https=)
IL (1) IL300145A (https=)
JO (1) JOP20230013A1 (https=)
MX (1) MX2023001335A (https=)
PH (1) PH12023550205A1 (https=)
WO (1) WO2022023514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) * 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
SI3873894T1 (sl) 2018-10-31 2023-08-31 Les Laboratoires Servier Nova sol Bcl-2 inhibitorja, z njo povezana kristalna oblika, postopek za pripravo le-teh in farmacevtski sestavki, ki jih vsebujejo

Also Published As

Publication number Publication date
CA3190276A1 (en) 2022-02-03
KR20230044452A (ko) 2023-04-04
CN116390735A (zh) 2023-07-04
WO2022023514A1 (en) 2022-02-03
IL300145A (en) 2023-03-01
MX2023001335A (es) 2023-04-27
BR112023001307A2 (pt) 2023-02-14
US20230270748A1 (en) 2023-08-31
CL2023000242A1 (es) 2023-11-10
PH12023550205A1 (en) 2024-06-24
EP4188387A1 (en) 2023-06-07
JP2023537290A (ja) 2023-08-31
JOP20230013A1 (ar) 2023-01-18
AU2021316674A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
Becker et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
Fiedler et al. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Degen et al. The hand‐foot‐syndrome associated with medical tumor therapy–classification and management
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
MX2025004156A (es) Composiciones topicas para el alivio del dolor.
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
AR050418A1 (es) Dosificacion fija de anticuerpos her
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
CR20230046A (es) Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma.
CL2023001639A1 (es) Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
deKernion The chemotherapy of advanced bladder carcinoma
CR20210210A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
Ben-Josef Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer
GT200500315A (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
Or et al. The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models
MX2022006884A (es) Composicion para cicatrizacion de heridas cronicas y aplicaciones de la misma.
IL183924A0 (en) Use of a combination of active agents in the preparation of pharmaceutical compositions
Froelich A Triplet Drug Combination Against Aggressive Breast Cancer
Barton Discontinuation of imatinib may be possible in chronic myelogenous leukemia.
AR122320A1 (es) Composiciones tópicas para el alivio del dolor